查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1614259

伊文氏肉瘤治疗药物市场：按治疗、阶段、适应症、最终用户、分销管道 - 2025-2030 年全球预测

Ewing Sarcoma Therapeutics Market by Treatment (Chemotherapy, Radiation Therapy, Surgery), Stage of Disease (Localized Ewing Sarcoma, Metastatic Ewing Sarcoma), Indication, End-User, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

伊文氏肉瘤治疗市场2023年估值为10.1亿美元，预计到2024年将达到10.8亿美元，复合年增长率为6.83%，预计到2030年将达到16.1亿美元。

伊文氏肉瘤治疗描述了针对伊文氏肉瘤的治疗方法的开发和商业化。伊文氏肉瘤是一种罕见的骨骼和软组织癌症，主要影响青少年和年轻人。这些治疗的需求源于伊文氏肉瘤的侵袭性，以及由于其复杂的病理生理学、復发和抗药性问题而迫切需要解决未满足的医疗需求。应用主要集中在化疗药物、标靶治疗以及基因治疗和免疫治疗等新治疗方法。最终用途包括医院、肿瘤中心和专科诊所。目前，该市场的驱动因素包括发病率上升、精准医疗的进步以及能够实现早期检测的诊断技术的改进。新的发展机会在于将人工智慧纳入个人化治疗计划和药物再利用策略，并考虑小型患者群体开发新药的挑战。生技公司、研究机构和製药公司之间的合作可以增加资源共用，降低研发成本和上市时间。然而，挑战仍然存在，例如临床试验的高成本、严格的监管要求以及可研究的患者群体有限，阻碍了更广泛的市场成长。智慧财产权障碍和潜在的伦理问题构成了进一步的限制，特别是对于基因治疗应用而言。创新领域包括开发用于早期检测和预后的生物标记、克服抗药性的联合治疗以及使用 CRISPR 技术进行标靶基因编辑。因此，确保策略伙伴关係并创造有利于诊断和治疗方法创新的环境可以增强竞争优势并改善治疗结果。对研发的持续投资以及监管合规的优先考虑应继续在克服现有市场挑战和确保该专业的持续成长方面发挥核心作用。

主要市场统计
基准年[2023] 10.1亿美元
预计年份 [2024] 10.8亿美元
预测年份 [2030] 16.1亿美元
复合年增长率（%） 6.83%

市场动态：揭示快速发展的伊文氏肉瘤药物市场的关键市场洞察

伊文氏肉瘤药物市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 全球伊文氏肉瘤盛行率不断上升
    • 加强对伊文氏肉瘤的认知计画和教育
  • 市场限制因素
    • 伊文氏肉瘤的治疗费用上涨
  • 市场机会
    • 活性化研发力度，引进伊文氏肉瘤的治疗方法
    • 伊文氏肉瘤标靶治疗的潜力不断增加
  • 市场挑战
    • 伊文氏肉瘤特异性药物开发与製造的复杂性

波特的五力：驾驭伊文氏肉瘤药物市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解伊文氏肉瘤药物市场的外部影响

外部宏观环境因素在塑造伊文氏肉瘤治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解伊文氏肉瘤治疗药物市场的竞争状况

伊文氏肉瘤治疗市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵伊文氏肉瘤治疗市场供应商的绩效评估

FPNV 定位矩阵是评估伊文氏肉瘤治疗市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，为尤文氏伊文氏肉瘤药物市场的成功指明道路

对伊文氏肉瘤药物市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球伊文氏肉瘤发生率增加
      • 加强对伊文氏肉瘤的认知计画和教育
    • 抑制因素
      • 伊文氏肉瘤的治疗费用很高。
    • 机会
      • 扩大研究和开发力度，引入伊文氏肉瘤的有效治疗方法
      • 伊文氏肉瘤标靶治疗的潜力增加
    • 任务
      • 伊文氏肉瘤特定药物开发与製造的复杂性
  • 市场区隔分析
    • 治疗：越来越需要放射线治疗来消灭癌细胞
    • 最终用户：透过医院和诊所更多地获得伊文氏肉瘤药物
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章伊文氏肉瘤药物市场（依治疗）

  • 化疗
  • 放射治疗
  • 外科手术
  • 标靶治疗

第七章依疾病阶段伊文氏肉瘤治疗药物市场

  • 局部伊文氏肉瘤
  • 转移性伊文氏肉瘤

第八章伊文氏肉瘤治疗药物市场（按适应症）

  • 阿斯金瘤
  • 骨肿瘤
  • 週边原始神经外胚层肿瘤
  • 软组织肿瘤

第九章伊文氏肉瘤治疗药物市场：依最终用户分类

  • 癌症治疗中心
  • 医院/诊所

第10章伊文氏肉瘤治疗药物市场：按分销管道

  • 医院药房
  • 网路药房

第十一章美洲伊文氏肉瘤治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太地区伊文氏肉瘤治疗药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲伊文氏肉瘤治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Inhiflex 报告治疗伊文氏肉瘤的第一期研究结果取得进展
    • 住友製药肿瘤公司的 TP-1287 获得治疗伊文氏肉瘤的孤儿药资格
    • 奈米医学在伊文氏肉瘤个人化治疗方面取得突破
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Amgen Inc.
  • Amneal Pharmaceuticals Inc.
  • AstraZeneca plc
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Johnson and Johnson, Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Sumitomo Pharma Oncology, Inc.
Product Code: MRR-CB04E05652A3

The Ewing Sarcoma Therapeutics Market was valued at USD 1.01 billion in 2023, expected to reach USD 1.08 billion in 2024, and is projected to grow at a CAGR of 6.83%, to USD 1.61 billion by 2030.

Ewing Sarcoma Therapeutics involves the development and commercialization of treatments specifically targeting Ewing Sarcoma, a rare form of cancer typically occurring in bones or soft tissue, affecting predominantly adolescents and young adults. The necessity of these therapeutics stems from the aggressive nature of Ewing Sarcoma and the urgency to address unmet medical needs due to its complex pathophysiology, recurrence, and resistance issues. Applications primarily focus on chemotherapeutic agents, targeted therapies, and emerging modalities like gene therapy and immunotherapy. End-use extends across hospitals, oncology centers, and specialized clinics. The market is currently driven by increasing incidence rates, advancements in precision medicine, and better diagnostic techniques enabling early detection. Emerging opportunities lie in the incorporation of Artificial Intelligence for personalized treatment plans and in drug repurposing strategies, given the challenges of developing new drugs for a small patient cohort. Collaborations between biotech firms, research institutes, and pharmaceutical companies could facilitate sharing of resources, thereby reducing R&D costs and time-to-market. However, challenges persist, including high costs of clinical trials, stringent regulatory requirements, and limited patient populations for testing, which hinder broader market growth. Intellectual Property obstacles and potential ethical concerns, particularly with gene therapy applications, present further limitations. Innovative areas may include the development of biomarkers for early detection and prognosis, combination therapies to overcome resistance, and leveraging CRISPR technologies for targeted gene editing. The Ewing Sarcoma Therapeutics market is predominantly research-driven with a niche focus; hence, ensuring strategic partnerships and fostering an environment conducive to innovation in diagnostics and treatment methodologies could bolster competitive advantage, potentially leading to enhanced therapeutic outcomes. Continuous investment in R&D and prioritizing regulatory compliance should remain central to overcoming existing market challenges and ensuring sustainable growth in this specialized field.

KEY MARKET STATISTICS
Base Year [2023] USD 1.01 billion
Estimated Year [2024] USD 1.08 billion
Forecast Year [2030] USD 1.61 billion
CAGR (%) 6.83%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Ewing Sarcoma Therapeutics Market

The Ewing Sarcoma Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of Ewing Sarcoma worldwide
    • Increasing awareness programs and education about Ewing sarcoma
  • Market Restraints
    • High cost of Ewing sarcoma treatments
  • Market Opportunities
    • Growing research & development activities to introduce effective Ewing sarcoma treatments
    • Increasing potential for targeted therapy for Ewing sarcoma
  • Market Challenges
    • Complexities in drug development and manufacturing specific to Ewing sarcoma

Porter's Five Forces: A Strategic Tool for Navigating the Ewing Sarcoma Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Ewing Sarcoma Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Ewing Sarcoma Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Ewing Sarcoma Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Ewing Sarcoma Therapeutics Market

A detailed market share analysis in the Ewing Sarcoma Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Ewing Sarcoma Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Ewing Sarcoma Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Ewing Sarcoma Therapeutics Market

A strategic analysis of the Ewing Sarcoma Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Ewing Sarcoma Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Amgen Inc., Amneal Pharmaceuticals Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Johnson and Johnson, Inc., Merck KGaA, Novartis AG, Pfizer Inc., Sanofi S.A., and Sumitomo Pharma Oncology, Inc..

Market Segmentation & Coverage

This research report categorizes the Ewing Sarcoma Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment, market is studied across Chemotherapy, Radiation Therapy, Surgery, and Targeted Therapy.
  • Based on Stage of Disease, market is studied across Localized Ewing Sarcoma and Metastatic Ewing Sarcoma.
  • Based on Indication, market is studied across Askin Tumor, Bone Tumor, Peripheral Primitive Neuroectodermal Tumor, and Soft Tissue Tumor.
  • Based on End-User, market is studied across Cancer Treatment Centers and Hospitals & Clinics.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies and Online Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of Ewing Sarcoma worldwide
      • 5.1.1.2. Increasing awareness programs and education about Ewing sarcoma
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of Ewing sarcoma treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing research & development activities to introduce effective Ewing sarcoma treatments
      • 5.1.3.2. Increasing potential for targeted therapy for Ewing sarcoma
    • 5.1.4. Challenges
      • 5.1.4.1. Complexities in drug development and manufacturing specific to Ewing sarcoma
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment: Growing need for radiation therapy to destroy cancer cells
    • 5.2.2. End-User: High accessibility of Ewing sarcoma therapeutics through hospitals & clinics
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Ewing Sarcoma Therapeutics Market, by Treatment

  • 6.1. Introduction
  • 6.2. Chemotherapy
  • 6.3. Radiation Therapy
  • 6.4. Surgery
  • 6.5. Targeted Therapy

7. Ewing Sarcoma Therapeutics Market, by Stage of Disease

  • 7.1. Introduction
  • 7.2. Localized Ewing Sarcoma
  • 7.3. Metastatic Ewing Sarcoma

8. Ewing Sarcoma Therapeutics Market, by Indication

  • 8.1. Introduction
  • 8.2. Askin Tumor
  • 8.3. Bone Tumor
  • 8.4. Peripheral Primitive Neuroectodermal Tumor
  • 8.5. Soft Tissue Tumor

9. Ewing Sarcoma Therapeutics Market, by End-User

  • 9.1. Introduction
  • 9.2. Cancer Treatment Centers
  • 9.3. Hospitals & Clinics

10. Ewing Sarcoma Therapeutics Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacies
  • 10.3. Online Pharmacies

11. Americas Ewing Sarcoma Therapeutics Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Ewing Sarcoma Therapeutics Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Ewing Sarcoma Therapeutics Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Inhibrx Reports Progress in Ewing Sarcoma Treatment with Phase 1 Trial Results
    • 14.3.2. Orphan Drug Designation Awarded to Sumitomo Pharma Oncology's TP-1287 for Ewing Sarcoma Treatment
    • 14.3.3. Breakthrough in Personalized Treatment for Ewing Sarcoma Using Nanomedicine
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Amgen Inc.
  • 3. Amneal Pharmaceuticals Inc.
  • 4. AstraZeneca plc
  • 5. Bayer AG
  • 6. Bristol-Myers Squibb Company
  • 7. Eli Lilly and Company
  • 8. F. Hoffmann-La Roche Ltd.
  • 9. GlaxoSmithKline PLC
  • 10. Johnson and Johnson, Inc.
  • 11. Merck KGaA
  • 12. Novartis AG
  • 13. Pfizer Inc.
  • 14. Sanofi S.A.
  • 15. Sumitomo Pharma Oncology, Inc.

LIST OF FIGURES

  • FIGURE 1. EWING SARCOMA THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. EWING SARCOMA THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS EWING SARCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS EWING SARCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC EWING SARCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC EWING SARCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. EWING SARCOMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. EWING SARCOMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. EWING SARCOMA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. EWING SARCOMA THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY LOCALIZED EWING SARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY METASTATIC EWING SARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY ASKIN TUMOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY BONE TUMOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY SOFT TISSUE TUMOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY CANCER TREATMENT CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS EWING SARCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC EWING SARCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 235. EWING SARCOMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 236. EWING SARCOMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023